Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis
There are conflicting reports on the results of several of the latest clinical trials related to the use of baricitinib in the management of COVID-19 patients. The aim of the current systematic review and meta-analysis was to evaluate the efficacy of baricitinib in COVID-19 patients. Databases like...
Gespeichert in:
| Veröffentlicht in: | Respiratory medicine 2022-10, Vol.202, p.106986-106986, Article 106986 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 106986 |
|---|---|
| container_issue | |
| container_start_page | 106986 |
| container_title | Respiratory medicine |
| container_volume | 202 |
| creator | Manoharan, Sivananthan Ying, Lee Ying |
| description | There are conflicting reports on the results of several of the latest clinical trials related to the use of baricitinib in the management of COVID-19 patients. The aim of the current systematic review and meta-analysis was to evaluate the efficacy of baricitinib in COVID-19 patients.
Databases like ScienceDirect, PubMed/Medline, Publons, Google Scholar and other sources like ClinicalTrials.gov, Cochrane, medRxiv, Research Square and reference lists were thoroughly searched.
Fifteen (15) articles which met the inclusion criteria were qualitatively and quantitatively analysed. Based on Cochrane and Newcastle-Ottawa Scale (NOS) risk of bias (RoB) analyses, 14/15 articles are grouped as high-quality. Meta-analyses revealed that randomised control trials (RCTs) and non-randomised control trials (nRCTs) statistically significantly reduced the mortality rate in COVID-19 patients, with a risk ratio (RR) in the fixed-effect model was RR = 0.64 [95% CI: 0.51 to 0.79; p |
| doi_str_mv | 10.1016/j.rmed.2022.106986 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9477792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0954611122002517</els_id><sourcerecordid>2717691143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-7b05dae40b0db3c20c91247b1363f3253223c02b5dd74647462435fe6dce0ad43</originalsourceid><addsrcrecordid>eNp9kc1uEzEUhS0EoqHwAiyQl2wm9d94MhICRSkUpEpIFNhaHvtOcTQzDr6eoLwAz41DSgUbFpat63M_X59DyHPOlpxxfbFdphH8UjAhSkG3K_2ALHgtRSWZVg_JgrW1qjTn_Iw8Qdwyxlql2GNyJjWvmViJBfl5GQFpZ1NwIYcpdDSBnx3QMaZsh5AP1E6e-oBgEeguxdsEiCFONEz0Zv3pptrEr5Wg-5BmLLUeXAZPdzYHmDK-oWuKB8wwloIr8H2AH7-RI2RbDnY4YMCn5FFvB4Rnd_s5-fLu7efN--r649WHzfq6cnJV56rpWO0tKNYx30knmGu5UE3HpZa9FOXrQjomutr7RmlVllCy7kF7B8x6Jc_J6xN3N3fFO1dGTHYwuxRGmw4m2mD-vZnCN3Mb96ZVTdO0ogBe3gFS_D4DZjMGdDAMdoI4oxENb3TLuZJFKk5SlyJigv7-Gc7MMUCzNccAzTFAcwqwNL34e8D7lj-JFcGrkwCKTcXMZNAVpx34kIr1xsfwP_4vBIyu5w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2717691143</pqid></control><display><type>article</type><title>Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via ScienceDirect (Elsevier)</source><creator>Manoharan, Sivananthan ; Ying, Lee Ying</creator><creatorcontrib>Manoharan, Sivananthan ; Ying, Lee Ying</creatorcontrib><description>There are conflicting reports on the results of several of the latest clinical trials related to the use of baricitinib in the management of COVID-19 patients. The aim of the current systematic review and meta-analysis was to evaluate the efficacy of baricitinib in COVID-19 patients.
Databases like ScienceDirect, PubMed/Medline, Publons, Google Scholar and other sources like ClinicalTrials.gov, Cochrane, medRxiv, Research Square and reference lists were thoroughly searched.
Fifteen (15) articles which met the inclusion criteria were qualitatively and quantitatively analysed. Based on Cochrane and Newcastle-Ottawa Scale (NOS) risk of bias (RoB) analyses, 14/15 articles are grouped as high-quality. Meta-analyses revealed that randomised control trials (RCTs) and non-randomised control trials (nRCTs) statistically significantly reduced the mortality rate in COVID-19 patients, with a risk ratio (RR) in the fixed-effect model was RR = 0.64 [95% CI: 0.51 to 0.79; p < 0.0001] and RR = 0.58 [95% CI: 0.45 to 0.73; p < 0.00001], respectively, with insignificant heterogeneity and no publication bias found. For block/reduce disease progression (BDP), baricitinib did not statistically significantly reduce disease progression for RCTs. The RR in the random effect model was RR = 0.80 [95% CI: 0.58 to 1.10: p = 0.17], with significant heterogeneity, where I2 was 60%. On the other hand, baricitinib statistically significantly reduced disease progression in nRCTs, as the RR of the fixed effect model was RR = 0.54 [95% CI: 0.37 to 0.78; p = 0.001] with insignificant heterogeneity.
The current meta-analyses revealed that baricitinib statistically significantly reduced mortality rate and disease progression in COVID-19 patients.
CRD42021281556
•Baricitinib statically reduced mortality rate in Covid-19 patients.•Baricitinib statically reduced disease progression in Covid-19 patients.•Based on risk of bias analysis, 14/15 articles are grouped as high-quality studies.</description><identifier>ISSN: 0954-6111</identifier><identifier>EISSN: 1532-3064</identifier><identifier>DOI: 10.1016/j.rmed.2022.106986</identifier><identifier>PMID: 36150282</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Azetidines ; Baricitinib ; COVID-19 ; COVID-19 Drug Treatment ; Disease Progression ; Humans ; Meta-analysis ; Mortality ; Purines ; Pyrazoles ; SARS-CoV-2 ; Sulfonamides ; Systematic review</subject><ispartof>Respiratory medicine, 2022-10, Vol.202, p.106986-106986, Article 106986</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><rights>2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-7b05dae40b0db3c20c91247b1363f3253223c02b5dd74647462435fe6dce0ad43</citedby><cites>FETCH-LOGICAL-c385t-7b05dae40b0db3c20c91247b1363f3253223c02b5dd74647462435fe6dce0ad43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.rmed.2022.106986$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36150282$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Manoharan, Sivananthan</creatorcontrib><creatorcontrib>Ying, Lee Ying</creatorcontrib><title>Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis</title><title>Respiratory medicine</title><addtitle>Respir Med</addtitle><description>There are conflicting reports on the results of several of the latest clinical trials related to the use of baricitinib in the management of COVID-19 patients. The aim of the current systematic review and meta-analysis was to evaluate the efficacy of baricitinib in COVID-19 patients.
Databases like ScienceDirect, PubMed/Medline, Publons, Google Scholar and other sources like ClinicalTrials.gov, Cochrane, medRxiv, Research Square and reference lists were thoroughly searched.
Fifteen (15) articles which met the inclusion criteria were qualitatively and quantitatively analysed. Based on Cochrane and Newcastle-Ottawa Scale (NOS) risk of bias (RoB) analyses, 14/15 articles are grouped as high-quality. Meta-analyses revealed that randomised control trials (RCTs) and non-randomised control trials (nRCTs) statistically significantly reduced the mortality rate in COVID-19 patients, with a risk ratio (RR) in the fixed-effect model was RR = 0.64 [95% CI: 0.51 to 0.79; p < 0.0001] and RR = 0.58 [95% CI: 0.45 to 0.73; p < 0.00001], respectively, with insignificant heterogeneity and no publication bias found. For block/reduce disease progression (BDP), baricitinib did not statistically significantly reduce disease progression for RCTs. The RR in the random effect model was RR = 0.80 [95% CI: 0.58 to 1.10: p = 0.17], with significant heterogeneity, where I2 was 60%. On the other hand, baricitinib statistically significantly reduced disease progression in nRCTs, as the RR of the fixed effect model was RR = 0.54 [95% CI: 0.37 to 0.78; p = 0.001] with insignificant heterogeneity.
The current meta-analyses revealed that baricitinib statistically significantly reduced mortality rate and disease progression in COVID-19 patients.
CRD42021281556
•Baricitinib statically reduced mortality rate in Covid-19 patients.•Baricitinib statically reduced disease progression in Covid-19 patients.•Based on risk of bias analysis, 14/15 articles are grouped as high-quality studies.</description><subject>Azetidines</subject><subject>Baricitinib</subject><subject>COVID-19</subject><subject>COVID-19 Drug Treatment</subject><subject>Disease Progression</subject><subject>Humans</subject><subject>Meta-analysis</subject><subject>Mortality</subject><subject>Purines</subject><subject>Pyrazoles</subject><subject>SARS-CoV-2</subject><subject>Sulfonamides</subject><subject>Systematic review</subject><issn>0954-6111</issn><issn>1532-3064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1uEzEUhS0EoqHwAiyQl2wm9d94MhICRSkUpEpIFNhaHvtOcTQzDr6eoLwAz41DSgUbFpat63M_X59DyHPOlpxxfbFdphH8UjAhSkG3K_2ALHgtRSWZVg_JgrW1qjTn_Iw8Qdwyxlql2GNyJjWvmViJBfl5GQFpZ1NwIYcpdDSBnx3QMaZsh5AP1E6e-oBgEeguxdsEiCFONEz0Zv3pptrEr5Wg-5BmLLUeXAZPdzYHmDK-oWuKB8wwloIr8H2AH7-RI2RbDnY4YMCn5FFvB4Rnd_s5-fLu7efN--r649WHzfq6cnJV56rpWO0tKNYx30knmGu5UE3HpZa9FOXrQjomutr7RmlVllCy7kF7B8x6Jc_J6xN3N3fFO1dGTHYwuxRGmw4m2mD-vZnCN3Mb96ZVTdO0ogBe3gFS_D4DZjMGdDAMdoI4oxENb3TLuZJFKk5SlyJigv7-Gc7MMUCzNccAzTFAcwqwNL34e8D7lj-JFcGrkwCKTcXMZNAVpx34kIr1xsfwP_4vBIyu5w</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Manoharan, Sivananthan</creator><creator>Ying, Lee Ying</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221001</creationdate><title>Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis</title><author>Manoharan, Sivananthan ; Ying, Lee Ying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-7b05dae40b0db3c20c91247b1363f3253223c02b5dd74647462435fe6dce0ad43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Azetidines</topic><topic>Baricitinib</topic><topic>COVID-19</topic><topic>COVID-19 Drug Treatment</topic><topic>Disease Progression</topic><topic>Humans</topic><topic>Meta-analysis</topic><topic>Mortality</topic><topic>Purines</topic><topic>Pyrazoles</topic><topic>SARS-CoV-2</topic><topic>Sulfonamides</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Manoharan, Sivananthan</creatorcontrib><creatorcontrib>Ying, Lee Ying</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Respiratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Manoharan, Sivananthan</au><au>Ying, Lee Ying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis</atitle><jtitle>Respiratory medicine</jtitle><addtitle>Respir Med</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>202</volume><spage>106986</spage><epage>106986</epage><pages>106986-106986</pages><artnum>106986</artnum><issn>0954-6111</issn><eissn>1532-3064</eissn><abstract>There are conflicting reports on the results of several of the latest clinical trials related to the use of baricitinib in the management of COVID-19 patients. The aim of the current systematic review and meta-analysis was to evaluate the efficacy of baricitinib in COVID-19 patients.
Databases like ScienceDirect, PubMed/Medline, Publons, Google Scholar and other sources like ClinicalTrials.gov, Cochrane, medRxiv, Research Square and reference lists were thoroughly searched.
Fifteen (15) articles which met the inclusion criteria were qualitatively and quantitatively analysed. Based on Cochrane and Newcastle-Ottawa Scale (NOS) risk of bias (RoB) analyses, 14/15 articles are grouped as high-quality. Meta-analyses revealed that randomised control trials (RCTs) and non-randomised control trials (nRCTs) statistically significantly reduced the mortality rate in COVID-19 patients, with a risk ratio (RR) in the fixed-effect model was RR = 0.64 [95% CI: 0.51 to 0.79; p < 0.0001] and RR = 0.58 [95% CI: 0.45 to 0.73; p < 0.00001], respectively, with insignificant heterogeneity and no publication bias found. For block/reduce disease progression (BDP), baricitinib did not statistically significantly reduce disease progression for RCTs. The RR in the random effect model was RR = 0.80 [95% CI: 0.58 to 1.10: p = 0.17], with significant heterogeneity, where I2 was 60%. On the other hand, baricitinib statistically significantly reduced disease progression in nRCTs, as the RR of the fixed effect model was RR = 0.54 [95% CI: 0.37 to 0.78; p = 0.001] with insignificant heterogeneity.
The current meta-analyses revealed that baricitinib statistically significantly reduced mortality rate and disease progression in COVID-19 patients.
CRD42021281556
•Baricitinib statically reduced mortality rate in Covid-19 patients.•Baricitinib statically reduced disease progression in Covid-19 patients.•Based on risk of bias analysis, 14/15 articles are grouped as high-quality studies.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36150282</pmid><doi>10.1016/j.rmed.2022.106986</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6111 |
| ispartof | Respiratory medicine, 2022-10, Vol.202, p.106986-106986, Article 106986 |
| issn | 0954-6111 1532-3064 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9477792 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via ScienceDirect (Elsevier) |
| subjects | Azetidines Baricitinib COVID-19 COVID-19 Drug Treatment Disease Progression Humans Meta-analysis Mortality Purines Pyrazoles SARS-CoV-2 Sulfonamides Systematic review |
| title | Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T00%3A28%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20baricitinib%20reduce%20mortality%20and%20disease%20progression%20in%20SARS-CoV-2%20virus%20infected%20patients?%20A%20systematic%20review%20and%20meta%20analysis&rft.jtitle=Respiratory%20medicine&rft.au=Manoharan,%20Sivananthan&rft.date=2022-10-01&rft.volume=202&rft.spage=106986&rft.epage=106986&rft.pages=106986-106986&rft.artnum=106986&rft.issn=0954-6111&rft.eissn=1532-3064&rft_id=info:doi/10.1016/j.rmed.2022.106986&rft_dat=%3Cproquest_pubme%3E2717691143%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2717691143&rft_id=info:pmid/36150282&rft_els_id=S0954611122002517&rfr_iscdi=true |